Europe IgA Nephropathy Market – Industry Trends and Forecast to 2028

  • Pharmaceutical
  • Published Report
  • Jun 2021
  • Europe
  • 350 Pages
  • No of Tables: 364
  • No of Figures: 49

Europe IgA Nephropathy Market, By Disease Type (Primary IgA Nephropathy and Secondary IgA Nephropathy), Symptoms (Hematuria, Proteinuria, Edema and Others), Type (Diagnosis and Treatment), Population Type (Pediatrics and Adults), Route of Administration (Oral, Parenteral and Others), End User (Hospitals, Clinics, Home Healthcare and Others), Distribution Channel (Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Others), Country (Germany, U.K., France, Italy, Spain, Russia, Netherlands, Switzerland, Turkey, Ireland, Poland, Hungary, Lithuania, Norway, Austria, Rest of Europe) Industry Trends and Forecast to 2028

Europe IgA Nephropathy Market Market Analysis and Insights: Europe IgA Nephropathy Market

 The IgA nephropathy market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses that the market is growing with a CAGR of 19.2% in the forecast period of 2021 to 2028 and is expected to reach USD 327.88 million by 2028 from USD 95.35 million in 2020. The increasing drug discoveries for IgA nephropathy are the major drivers which drives the demand of the market in the forecast period. The rise in IgA nephropathy disorder leads to increase the burden of disease which will increase the demand for the diagnosis and treatment products, thus acts as driver for the IgA nephropathy market growth.

IgA nephropathy also known as Berger's disease is a kidney disease caused by the build-up of IgA deposits in the kidneys which cause inflammation and damage to the kidney tissues. Antibodies such as IgA are proteins produced by the immune system to shield the body from foreign substances including bacteria and viruses. The complication of this disease is the ESKD which then need dialysis for the treatment.

The increasing IgA nephropathy targeted pipeline drugs allows the potential candidate to show the efficacy for IgA nephropathy treatment hence acts as driver for the IgA nephropathy market. The cost of treatment of IgA nephropathy increase the pocket burden for patient in case of where reimbursement is absent hence acts as restraint for the IgA nephropathy market growth. Collaboration of market players for drug development increases the presence and innovation in the market hence acting as opportunity for the IgA nephropathy market growth. Side effects associated with the treatment of IgA nephropathy and the COVID-19 impact on immunosuppressive drugs market acts as challenge for the IgA nephropathy market growth.

The IgA nephropathy market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the IgA nephropathy market scenario contact Data Bridge Market Research for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.

Europe IgA Nephropathy Market IgA Nephropathy Market Scope and Market Size

The IgA nephropathy market is segmented on the basis of the disease type, symptoms, type, population type, route of administration, end user and distribution channel. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

  • On the basis of disease type, the IgA nephropathy market is segmented into primary IgA nephropathy and secondary IgA nephropathy. In 2021, primary IgA nephropathy segment is expected to dominate the market because the incidence of primary IgA nephropathy is more and can be diagnosed by blood or urine test easily.
  • On the basis of symptoms, the IgA nephropathy market is segmented into hematuria, proteinuria, edema and others. In 2021, hematuria segment is expected to dominate the market as it is the most common and frequently used parameter for clinical examination and is detected by the amount of blood in the urine showing the occurrence of disease in the kidney.
  • On the basis of type, the IgA nephropathy market is segmented into diagnosis and treatment. In 2021, the diagnosis segment is expected to dominate the market due to the fact that prior given the treatment, the proper detection and tracing of the IgA nephropathy is necessary which is possible only through the primary detection such as blood and urine test and confirmatory detection by kidney biopsy which are the major factor of this segment to dominate.
  • On the basis of population type, the IgA nephropathy market is segmented into pediatrics and adults. In 2021, the adults segment is expected to show the significant growth because the studies showed the connection of this disease with ageing.
  • On the basis of route of administration, the IgA nephropathy market is segmented into oral, parenteral and others. In 2021, the oral segment is expected to dominate the market due to the wide variety of oral product portfolio available in the interstate commerce by the market which increase the market of this segment.
  • On the basis of end user, the IgA nephropathy market is segmented into hospitals, clinics, home healthcare and others. In 2021, hospitals segment is expected to dominate the market due to its strong financial structure.
  • On the basis of distribution channel, the IgA nephropathy market is segmented into direct tender, hospital pharmacy, retail pharmacy, online pharmacy and others. In 2021, direct tender segment accelerates the revenue growth as well as provides tax benefits owing to which the direct tender segment is flourishing for the last few years, henceforth, affirmative illustrating the further growth of the market.

 IgA Nephropathy Market Country Level Analysis

IgA nephropathy market is analysed and market size information is provided by the country, disease type, symptoms, type, population type, route of administration, end user and distribution channel as referenced above.

The countries covered in the IgA nephropathy market report are the Germany, U.K., France, Italy, Spain, Russia, Netherlands, Switzerland, Turkey, Ireland, Poland, Hungary, Lithuania, Norway, Austria, and Rest of Europe.

Europe is expected to grow with the significant growth rate in the forecast period of 2021 to 2028 due to more advancement and rise in demand for more IgA nephropathy product and services. The U.K. is dominating the European market with the increasing advancement in IgA nephropathy’ industry in the region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Increasing collaboration by the player for Advanced IgA nephropathy is Creating New Opportunities for Players in the IgA Nephropathy Market

IgA nephropathy Market also provides you with detailed market analysis for every country growth. Additionally, it provides data regarding acquisition and agreement among the major market plyers and start-up companies. Moreover, growing impact of research and development activities on IgA nephropathy market growth pace. The data is available for historic period 2010 to 2019.

Competitive Landscape and IgA Nephropathy Market Share Analysis

The IgA nephropathy market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breadth, application dominance and technology lifeline curve. The above data points provided are only related to the company’s focus related to the IgA nephropathy market.

The major players covered in the report are Novartis AG, Pfizer Inc., Zydus Cadila, Fresenius Kabi USA (a subsidiary of Fresenius SE & Co. KGaA), Teva Pharmaceutical USA, Inc. (a subsidiary of Teva Pharmaceuticals Industries Ltd.), Hikma Pharmaceuticals PLC, LUPIN, Accord Health, Viatris Inc., Seimens Healthcare GmBH (a subsidiary of Seimens Healthineers AG), ARAKAY USA, Inc., Merck Sharp & Dohme. (a subsidiary of Merck & Co., Inc), Alembic Pharmaceuticals Limited, Strides Pharma Science Limited, and Apotex Inc., among other domestic and Europe players. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Many contracts and agreements are also initiated by the companies’ worldwide which are also accelerating the IgA nephropathy market.

For instance,

  • In March 2017, Apotex Inc. Announced that they have invested USD 184 Million Investment to Grow U.S. Manufacturing Presence, this is the Expansion Plan Comprises Company's Largest Investment in the United States. This has increased the company manufacturing to meet the demand for the product

Collaboration, joint ventures and other strategies by the market players is enhancing the company impression in the IgA nephropathy market which also provides the benefit for organisation to improve their IgA nephropathy sales growth.

Customization Available: Europe IgA nephropathy Market

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customised to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analysed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Factbook) or can assist you in creating presentations from the data sets available in the report.


SKU-

TABLE 1 EUROPE IGA NEPHROPATHY MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 2 EUROPE PRIMARY IGA NEPHROPATHY IN IGA NEPHROPATHY MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 3 EUROPE SECONDARY IGA NEPHROPATHY IN IGA NEPHROPATHY MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 4 EUROPE IGA NEPHROPATHY MARKET, BY SYMPTOMS, 2019-2028 (USD MILLION)

TABLE 5 EUROPE HEMATURIA IN IGA NEPHROPATHY MARKET, BY SYMPTOMS, 2019-2028 (USD MILLION)

TABLE 6 EUROPE PROTEINURIA IN IGA NEPHROPATHY MARKET, BY SYMPTOMS, 2019-2028 (USD MILLION)

TABLE 7 EUROPE EDEMA IN IGA NEPHROPATHY MARKET, BY SYMPTOMS, 2019-2028 (USD MILLION)

TABLE 8 EUROPE OTHERS IN IGA NEPHROPATHY MARKET, BY SYMPTOMS, 2019-2028 (USD MILLION)

TABLE 9 EUROPE IGA NEPHROPATHY MARKET, BY PRODUCT TYPE, 2019-2028 (USD MILLION)

TABLE 10 EUROPE DIAGNOSIS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 11 EUROPE DIAGNOSIS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 12 EUROPE URINE TEST IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 13 EUROPE TREATMENT IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 14 EUROPE TREATMENT IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 15 EUROPE TREATMENT BY BLOOD PRESSURE LOWERING AGENTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 16 EUROPE TREATMENT BY ACE-INHIBITOR IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 17 EUROPE TREATMENT BY ANGIOTENSIN RECEPTOR BLOCKERS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 18 EUROPE TREATMENT BY IMMUNOSUPPRESSANT IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 19 EUROPE TREATMENT BY CORTICOSTEROIDS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 20 EUROPE TREATMENT BY DIURETICS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 21 EUROPE TREATMENT BY DIURETICS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 22 EUROPE TREATMENT BY SUPPLEMENTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 23 EUROPE IGA NEPHROPATHY MARKET, BY POPULATION TYPE, 2019-2028 (USD MILLION)

TABLE 24 EUROPE ADUTLS IN IGA NEPHROPATHY MARKET, BY POPULATION TYPE, 2019-2028 (USD MILLION)

TABLE 25 EUROPE CHILDREN IN IGA NEPHROPATHY MARKET, BY POPULATION TYPE, 2019-2028 (USD MILLION)

TABLE 26 EUROPE IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 27 EUROPE ORAL ADMINISTRATION IN IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 28 EUROPE ORAL ADMINISTRATION IN IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 29 EUROPE PARENTERAL IN IGA NEPHROPATHY MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 30 EUROPE PARENTERAL ADMINISTRATION IN IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 31 EUROPE OTHERS IN IGA NEPHROPATHY MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 32 EUROPE IGA NEPHROPATHY MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 33 EUROPE HOSPITALS IN IGA NEPHROPATHY MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 34 SPECIALTY CLINICS IN IGA NEPHROPATHY MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 35 EUROPE HOME HEALTHCARE IN IGA NEPHROPATHY MARKET, BY REGION, 20190-2028 (USD MILLION)

TABLE 36 EUROPE OTHERS IN IGA NEPHROPATHY MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 37 EUROPE IGA NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 38 EUROPE HOPSITAL PHARMACY IN IGA NEPHROPATHY MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 39 EUROPE RETAIL PHARMACY IN IGA NEPHROPATHY MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 40 EUROPE ONLINE PARMACY IN IGA NEPHROPATHY MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 41 EUROPE DIRECT TENDER IN IGA NEPHROPATHY MARKET, BY REGION, 2018-2028 (USD MILLION)

TABLE 42 EUROPE OTHERS IN IGA NEPHROPATHY MARKET, BY REGION, 2018-2028 (USD MILLION)

TABLE 43 EUROPE IGA NEPHROPATHY MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 44 EUROPE IGA NEPHROPATHY MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 45 EUROPE IGA NEPHROPATHY MARKET, BY SYMPTOMS, 2019-2028 (USD MILLION)

TABLE 46 EUROPE IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 47 EUROPE DIAGNOSIS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 48 EUROPE DIAGNOSIS BY URINE TESTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 49 EUROPE TREATMENT IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 50 EUROPE TREATMENT BY BLOOD PRESSURE LOWERING AGENTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 51 EUROPE TREATMENT BY ACE-INHIBITOR IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 52 EUROPE TREATMENT BY ANGIOTENSIN RECEPTOR BLOCKERS IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 53 EUROPE TREATMENT BY IMMUNOSUPPRESSAN IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 54 EUROPE TREATMENT BY CORTICOSTEROIDS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 55 EUROPE TREATMENT BY DIURETICS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 56 EUROPE TREATMENT BY LOWER BLOOD CHOLESTEROL AGENTS IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 57 EUROPE TREATMENT BY SUPPLEMENTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 58 EUROPE IGA NEPHROPATHY MARKET, BY POPULATION TYPE, 2019-2028 (USD MILLION)

TABLE 59 EUROPE IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 60 EUROPE ORAL ADMINISTRATION IN IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 61 EUROPE PARENTERAL ADMINISTRATION IN IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 62 EUROPE IGA NEPHROPATHY MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 63 EUROPE IGA NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 64 GERMANY IGA NEPHROPATHY MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 65 GERMANY IGA NEPHROPATHY MARKET, BY SYMPTOMS, 2019-2028 (USD MILLION)

TABLE 66 GERMANY IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 67 GERMANY DIAGNOSIS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 68 GERMANY DIAGNOSIS BY URINE TESTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 69 GERMANY TREATMENT IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 70 GERMANY TREATMENT BY BLOOD PRESSURE LOWERING AGENTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 71 GERMANY TREATMENT BY ACE-INHIBITOR IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 72 GERMANY TREATMENT BY ANGIOTENSIN RECEPTOR BLOCKERS IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 73 GERMANY TREATMENT BY IMMUNOSUPPRESSAN IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 74 GERMANY TREATMENT BY CORTICOSTEROIDS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 75 GERMANY IGA TREATMENT BY DIURETICS IN NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 76 GERMANY TREATMENT BY LOWER BLOOD CHOLESTEROL AGENTS IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 77 GERMANY TREATMENT BY SUPPLEMENTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 78 GERMANY IGA NEPHROPATHY MARKET, BY POPULATION TYPE, 2019-2028 (USD MILLION)

TABLE 79 GERMANY IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 80 GERMANY ORAL ADMINISTRATION IN IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 81 GERMANY PARENTERAL ADMINISTRATION IN IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINSITRATION, 2019-2028 (USD MILLION)

TABLE 82 GERMANY IGA NEPHROPATHY MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 83 GERMANY IGA NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 84 U.K. IGA NEPHROPATHY MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 85 U.K. IGA NEPHROPATHY MARKET, BY SYMPTOMS, 2019-2028 (USD MILLION)

TABLE 86 U.K. IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 87 U.K. DIAGNOSIS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 88 U.K. DIAGNOSIS BY URINE TESTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 89 U.K. TREATMENT IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 90 U.K. TREATMENT BY BLOOD PRESSURE LOWERING AGENTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 91 U.K. TREATMENT BY ACE-INHIBITOR IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 92 U.K. TREATMENT BY ANGIOTENSIN RECEPTOR BLOCKERS IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 93 U.K. TREATMENT BY IMMUNOSUPPRESSAN IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 94 U.K. TREATMENT BY CORTICOSTEROIDS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 95 U.K. TREATMENT BY DIURETICS IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 96 U.K. TREATMENT BY LOWER BLOOD CHOLESTEROL AGENTS IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 97 U.K. TREATMENT BY SUPPLEMENTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 98 U.K. IGA NEPHROPATHY MARKET, BY POPULATION TYPE, 2019-2028 (USD MILLION)

TABLE 99 U.K. IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 100 U.K. ORAL ADMINISTRATION IN IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 101 U.K. PARENTERAL ADMINISTRATION IN IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 102 U.K. IGA NEPHROPATHY MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 103 U.K. IGA NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 104 ITALY IGA NEPHROPATHY MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 105 ITALY IGA NEPHROPATHY MARKET, BY SYMPTOMS, 2019-2028 (USD MILLION)

TABLE 106 ITALY IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 107 ITALY DIAGNOSIS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 108 ITALY DIAGNOSIS BY URINE TESTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 109 ITALY TREATMENT IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 110 ITALY TREATMENT BY BLOOD PRESSURE LOWERING AGENTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 111 ITALY TREATMENT BY ACE-INHIBITOR IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 112 ITALY TREATMENT BY ANGIOTENSIN RECEPTOR BLOCKERS IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 113 ITALY TREATMENT BY IMMUNOSUPPRESSAN IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 114 ITALY TREATMENT BY CORTICOSTEROIDS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 115 ITALY TREATMENT BY DIURETICS IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 116 ITALY TREATMENT BY LOWER BLOOD CHOLESTEROL AGENTS IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 117 ITALY TREATMENT BY SUPPLEMENTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 118 ITALY IGA NEPHROPATHY MARKET, BY POPULATION TYPE, 2019-2028 (USD MILLION)

TABLE 119 ITALY IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 120 ITALY ORAL ADMINISTRATION IN IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 121 ITALY PARENTERAL ADMINISTRATION IN IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 122 ITALY IGA NEPHROPATHY MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 123 ITALY IGA NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 124 FRANCE IGA NEPHROPATHY MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 125 FRANCE IGA NEPHROPATHY MARKET, BY SYMPTOMS, 2019-2028 (USD MILLION)

TABLE 126 FRANCE IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 127 FRANCE DIAGNOSIS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 128 FRANCE DIAGNOSIS BY URINE TESTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 129 FRANCE TREATMENT IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 130 FRANCE TREATMENT BY BLOOD PRESSURE LOWERING AGENTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 131 FRANCE TREATMENT BY ACE-INHIBITOR IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 132 FRANCE TREATMENT BY ANGIOTENSIN RECEPTOR BLOCKERS IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 133 FRANCE TREATMENT BY IMMUNOSUPPRESSAN IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 134 FRANCE TREATMENT BY CORTICOSTEROIDS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 135 FRANCE TREATMENT BY DIURETICS IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 136 FRANCE TREATMENT BY LOWER BLOOD CHOLESTEROL AGENTS IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 137 FRANCE TREATMENT BY SUPPLEMENTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 138 FRANCE IGA NEPHROPATHY MARKET, BY POPULATION TYPE 2019-2028 (USD MILLION)

TABLE 139 FRANCE IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 140 FRANCE ORAL ADMINISTRATION IN IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 141 FRANCE PARENTERAL ADMINISTRATION IN IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 142 FRANCE IGA NEPHROPATHY MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 143 FRANCE IGA NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 144 SPAIN IGA NEPHROPATHY MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 145 SPAIN IGA NEPHROPATHY MARKET, BY SYMPTOMS, 2019-2028 (USD MILLION)

TABLE 146 SPAIN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 147 SPAIN DIAGNOSIS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 148 SPAIN DIAGNOSIS BY URINE TESTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 149 SPAIN TREATMENT IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 150 SPAIN TREATMENT BY BLOOD PRESSURE LOWERING AGENTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 151 SPAIN TREATMENT BY ACE-INHIBITOR IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 152 SPAIN TREATMENT BY ANGIOTENSIN RECEPTOR BLOCKERS IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 153 SPAIN TREATMENT BY IMMUNOSUPPRESSAN IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 154 SPAIN TREATMENT BY CORTICOSTEROIDS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 155 SPAIN TREATMENT BY DIURETICS IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 156 SPAIN TREATMENT BY LOWER BLOOD CHOLESTEROL AGENTS IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 157 SPAIN TREATMENT BY SUPPLEMENTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 158 SPAIN IGA NEPHROPATHY MARKET, BY POPULATION TYPE, 2019-2028 (USD MILLION)

TABLE 159 SPAIN IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 160 SPAIN ORAL ADMINISTRATION IN IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 161 SPAIN PARENTERAL ADMINISTRATION IN IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 162 SPAIN IGA NEPHROPATHY MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 163 SPAIN IGA NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 164 NETHERLAND IGA NEPHROPATHY MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 165 NETHERLAND IGA NEPHROPATHY MARKET, BY SYMPTOMS, 2019-2028 (USD MILLION)

TABLE 166 NETHERLAND IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 167 NETHERLAND DIAGNOSIS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 168 NETHERLAND DIAGNOSIS BY URINE TESTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 169 NETHERLAND TREATMENT IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 170 NETHERLAND TREATMENT BY BLOOD PRESSURE LOWERING AGENTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 171 NETHERLAND TREATMENT BY ACE-INHIBITOR IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 172 NETHERLAND TREATMENT BY ANGIOTENSIN RECEPTOR BLOCKERS IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 173 NETHERLAND TREATMENT BY IMMUNOSUPPRESSAN IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 174 NETHERLAND TREATMENT BY CORTICOSTEROIDS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 175 NETHERLAND TREATMENT BY DIURETICS IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 176 NETHERLAND TREATMENT BY LOWER BLOOD CHOLESTEROL AGENTS IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 177 NETHERLAND TREATMENT BY SUPPLEMENTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 178 NETHERLAND IGA NEPHROPATHY MARKET, BY POPULATION TYPE, 2019-2028 (USD MILLION)

TABLE 179 NETHERLAND IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 180 NETHERLAND ORAL ADMINISTRATION IN IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 181 NETHERLAND PARENTERAL ADMINISTRATION IN IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 182 NETHERLAND IGA NEPHROPATHY MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 183 NETHERLAND IGA NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 184 RUSSIA IGA NEPHROPATHY MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 185 RUSSIA IGA NEPHROPATHY MARKET, BY SYMPTOMS, 2019-2028 (USD MILLION)

TABLE 186 RUSSIA IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 187 RUSSIA DIAGNOSIS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 188 RUSSIA DIAGNOSIS BY URINE TESTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 189 RUSSIA TREATMENT IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 190 RUSSIA TREATMENT BY BLOOD PRESSURE LOWERING AGENTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 191 RUSSIA TREATMENT BY ACE-INHIBITOR IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 192 RUSSIA TREATMENT BY ANGIOTENSIN RECEPTOR BLOCKERS IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 193 RUSSIA TREATMENT BY IMMUNOSUPPRESSAN IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 194 RUSSIA TREATMENT BY CORTICOSTEROIDS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 195 RUSSIA TREATMENT BY DIURETICS IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 196 RUSSIA TREATMENT BY LOWER BLOOD CHOLESTEROL AGENTS IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 197 RUSSIA TREATMENT BY SUPPLEMENTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 198 RUSSIA IGA NEPHROPATHY MARKET, BY POPULATION TYPE, 2019-2028 (USD MILLION)

TABLE 199 RUSSIA IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 200 RUSSIA ORAL ADMINISTRATION IN IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 201 RUSSIA PARENTERAL ADMINISTRATION IN IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 202 RUSSIA IGA NEPHROPATHY MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 203 RUSSIA IGA NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 204 SWITZERLAND IGA NEPHROPATHY MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 205 SWITZERLAND IGA NEPHROPATHY MARKET, BY SYMPTOMS, 2019-2028 (USD MILLION)

TABLE 206 SWITZERLAND IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 207 SWITZERLAND DIAGNOSIS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 208 SWITZERLAND DIAGNOSIS BY URINE TESTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 209 SWITZERLAND TREATMENT IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 210 SWITZERLAND TREATMENT BY BLOOD PRESSURE LOWERING AGENTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 211 SWITZERLAND TREATMENT BY ACE-INHIBITOR IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 212 SWITZERLAND TREATMENT BY ANGIOTENSIN RECEPTOR BLOCKERS IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 213 SWITZERLAND TREATMENT BY IMMUNOSUPPRESSAN IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 214 SWITZERLAND TREATMENT BY CORTICOSTEROIDS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 215 SWITZERLAND TREATMENT BY DIURETICS IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 216 SWITZERLAND TREATMENT BY LOWER BLOOD CHOLESTEROL AGENTS IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 217 SWITZERLAND TREATMENT BY SUPPLEMENTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 218 SWITZERLAND IGA NEPHROPATHY MARKET, BY POPULATION TYPE, 2019-2028 (USD MILLION)

TABLE 219 SWITZERLAND IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 220 SWITZERLAND ORAL ADMINISTRATION IN IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 221 SWITZERLAND PARENTERAL ADMINISTRATION IN IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 222 SWITZERLAND IGA NEPHROPATHY MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 223 SWITZERLAND IGA NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 224 TURKEY IGA NEPHROPATHY MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 225 TURKEY IGA NEPHROPATHY MARKET, BY SYMPTOMS, 2019-2028 (USD MILLION)

TABLE 226 TURKEY IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 227 TURKEY DIAGNOSIS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 228 TURKEY DIAGNOSIS BY URINE TESTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 229 TURKEY TREATMENT IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 230 TURKEY TREATMENT BY BLOOD PRESSURE LOWERING AGENTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 231 TURKEY TREATMENT BY ACE-INHIBITOR IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 232 TURKEY TREATMENT BY ANGIOTENSIN RECEPTOR BLOCKERS IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 233 TURKEY TREATMENT BY IMMUNOSUPPRESSAN IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 234 TURKEY TREATMENT BY CORTICOSTEROIDS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 235 TURKEY TREATMENT BY DIURETICS IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 236 TURKEY TREATMENT BY LOWER BLOOD CHOLESTEROL AGENTS IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 237 TURKEY TREATMENT BY SUPPLEMENTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 238 TURKEY IGA NEPHROPATHY MARKET, BY POPULATION TYPE, 2019-2028 (USD MILLION)

TABLE 239 TURKEY IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 240 TURKEY ORAL ADMINISTRATION IN IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 241 TURKEY PARENTERAL ADMINISTRATION IN IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 242 TURKEY IGA NEPHROPATHY MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 243 TURKEY IGA NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 244 AUSTRIA IGA NEPHROPATHY MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 245 AUSTRIA IGA NEPHROPATHY MARKET, BY SYMPTOMS, 2019-2028 (USD MILLION)

TABLE 246 AUSTRIA IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 247 AUSTRIA DIAGNOSIS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 248 AUSTRIA DIAGNOSIS BY URINE TESTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 249 AUSTRIA TREATMENT IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 250 AUSTRIA TREATMENT BY BLOOD PRESSURE LOWERING AGENTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 251 AUSTRIA TREATMENT BY ACE-INHIBITOR IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 252 AUSTRIA TREATMENT BY ANGIOTENSIN RECEPTOR BLOCKERS IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 253 AUSTRIA TREATMENT BY IMMUNOSUPPRESSAN IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 254 AUSTRIA TREATMENT BY CORTICOSTEROIDS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 255 AUSTRIA TREATMENT BY DIURETICS IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 256 AUSTRIA TREATMENT BY LOWER BLOOD CHOLESTEROL AGENTS IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 257 AUSTRIA TREATMENT BY SUPPLEMENTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 258 AUSTRIA IGA NEPHROPATHY MARKET, BY POPULATION TYPE, 2019-2028 (USD MILLION)

TABLE 259 AUSTRIA IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 260 AUSTRIA ORAL ADMINISTRATION IN IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 261 AUSTRIA PARENTERAL ADMINISTRATION IN IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 262 AUSTRIA IGA NEPHROPATHY MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 263 AUSTRIA IGA NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 264 NORWAY IGA NEPHROPATHY MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 265 NORWAY IGA NEPHROPATHY MARKET, BY SYMPTOMS, 2019-2028 (USD MILLION)

TABLE 266 NORWAY IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 267 NORWAY DIAGNOSIS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 268 NORWAY DIAGNOSIS BY URINE TESTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 269 NORWAY TREATMENT IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 270 NORWAY TREATMENT BY BLOOD PRESSURE LOWERING AGENTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 271 NORWAY TREATMENT BY ACE-INHIBITOR IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 272 NORWAY TREATMENT BY ANGIOTENSIN RECEPTOR BLOCKERS IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 273 NORWAY TREATMENT BY IMMUNOSUPPRESSAN IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 274 NORWAY TREATMENT BY CORTICOSTEROIDS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 275 NORWAY TREATMENT BY DIURETICS IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 276 NORWAY TREATMENT BY LOWER BLOOD CHOLESTEROL AGENTS IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 277 NORWAY TREATMENT BY SUPPLEMENTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 278 NORWAY IGA NEPHROPATHY MARKET, BY POPULATION TYPE, 2019-2028 (USD MILLION)

TABLE 279 NORWAY IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 280 NORWAY ORAL ADMINISTRATION IN IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 281 NORWAY PARENTERAL ADMINISTRATION IN IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 282 NORWAY IGA NEPHROPATHY MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 283 NORWAY IGA NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 284 HUNGARY IGA NEPHROPATHY MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 285 HUNGARY IGA NEPHROPATHY MARKET, BY SYMPTOMS, 2019-2028 (USD MILLION)

TABLE 286 HUNGARY IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 287 HUNGARY DIAGNOSIS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 288 HUNGARY DIAGNOSIS BY URINE TESTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 289 HUNGARY TREATMENT IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 290 HUNGARY TREATMENT BY BLOOD PRESSURE LOWERING AGENTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 291 HUNGARY TREATMENT BY ACE-INHIBITOR IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 292 HUNGARY TREATMENT BY ANGIOTENSIN RECEPTOR BLOCKERS IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 293 HUNGARY TREATMENT BY IMMUNOSUPPRESSAN IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 294 HUNGARY TREATMENT BY CORTICOSTEROIDS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 295 HUNGARY TREATMENT BY DIURETICS IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 296 HUNGARY TREATMENT BY LOWER BLOOD CHOLESTEROL AGENTS IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 297 HUNGARY TREATMENT BY SUPPLEMENTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 298 HUNGARY IGA NEPHROPATHY MARKET, BY POPULATION TYPE, 2019-2028 (USD MILLION)

TABLE 299 HUNGARY IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 300 HUNGARY ORAL ADMINISTRATION IN IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 301 HUNGARY PARENTERAL ADMINISTRATION IN IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 302 HUNGARY IGA NEPHROPATHY MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 303 HUNGARY IGA NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 304 LITHUANIA IGA NEPHROPATHY MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 305 LITHUANIA IGA NEPHROPATHY MARKET, BY SYMPTOMS, 2019-2028 (USD MILLION)

TABLE 306 LITHUANIA IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 307 LITHUANIA DIAGNOSIS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 308 LITHUANIA DIAGNOSIS BY URINE TESTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 309 LITHUANIA TREATMENT IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 310 LITHUANIA TREATMENT BY BLOOD PRESSURE LOWERING AGENTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 311 LITHUANIA TREATMENT BY ACE-INHIBITOR IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 312 LITHUANIA TREATMENT BY ANGIOTENSIN RECEPTOR BLOCKERS IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 313 LITHUANIA TREATMENT BY IMMUNOSUPPRESSAN IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 314 LITHUANIA TREATMENT BY CORTICOSTEROIDS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 315 LITHUANIA TREATMENT BY DIURETICS IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 316 LITHUANIA TREATMENT BY LOWER BLOOD CHOLESTEROL AGENTS IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 317 LITHUANIA TREATMENT BY SUPPLEMENTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 318 LITHUANIA IGA NEPHROPATHY MARKET, BY POPULATION TYPE, 2019-2028 (USD MILLION)

TABLE 319 LITHUANIA IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 320 LITHUANIA ORAL ADMINISTRATION IN IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 321 LITHUANIA PARENTERAL ADMINISTRATION IN IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 322 LITHUANIA IGA NEPHROPATHY MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 323 LITHUANIA IGA NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 324 IRELAND IGA NEPHROPATHY MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 325 IRELAND IGA NEPHROPATHY MARKET, BY SYMPTOMS, 2019-2028 (USD MILLION)

TABLE 326 IRELAND IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 327 IRELAND DIAGNOSIS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 328 IRELAND DIAGNOSIS BY URINE TESTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 329 IRELAND TREATMENT IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 330 IRELAND TREATMENT BY BLOOD PRESSURE LOWERING AGENTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 331 IRELAND TREATMENT BY ACE-INHIBITOR IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 332 IRELAND TREATMENT BY ANGIOTENSIN RECEPTOR BLOCKERS IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 333 IRELAND TREATMENT BY IMMUNOSUPPRESSAN IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 334 IRELAND TREATMENT BY CORTICOSTEROIDS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 335 IRELAND TREATMENT BY DIURETICS IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 336 IRELAND TREATMENT BY LOWER BLOOD CHOLESTEROL AGENTS IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 337 IRELAND TREATMENT BY SUPPLEMENTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 338 IRELAND IGA NEPHROPATHY MARKET, BY POPULATION TYPE, 2019-2028 (USD MILLION)

TABLE 339 IRELAND IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 340 IRELAND ORAL ADMINISTRATION IN IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 341 IRELAND PARENTERAL ADMINISTRATION IN IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 342 IRELAND IGA NEPHROPATHY MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 343 IRELAND IGA NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 344 POLAND IGA NEPHROPATHY MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 345 POLAND IGA NEPHROPATHY MARKET, BY SYMPTOMS, 2019-2028 (USD MILLION)

TABLE 346 POLAND IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 347 POLAND DIAGNOSIS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 348 POLAND DIAGNOSIS BY URINE TESTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 349 POLAND TREATMENT IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 350 POLAND TREATMENT BY BLOOD PRESSURE LOWERING AGENTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 351 POLAND TREATMENT BY ACE-INHIBITOR IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 352 POLAND TREATMENT BY ANGIOTENSIN RECEPTOR BLOCKERS IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 353 POLAND TREATMENT BY IMMUNOSUPPRESSAN IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 354 POLAND TREATMENT BY CORTICOSTEROIDS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 355 POLAND TREATMENT BY DIURETICS IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 356 POLAND TREATMENT BY LOWER BLOOD CHOLESTEROL AGENTS IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 357 POLAND TREATMENT BY SUPPLEMENTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 358 POLAND IGA NEPHROPATHY MARKET, BY POPULATION TYPE, 2019-2028 (USD MILLION)

TABLE 359 POLAND IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 360 POLAND ORAL ADMINISTRATION IN IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 361 POLAND PARENTERAL ADMINISTRATION IN IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 362 POLAND IGA NEPHROPATHY MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 363 POLAND IGA NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 364 REST OF EUROPE IGA NEPHROPATHY MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

CHOOSE LICENCE TYPE
  • 4200.00
  • 3500.00
  • 2000.00
  • 5500.00
  • 7500.00
Why Choose Us
Unlocking New Opportunities on this Report Post Covid-19

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions